What does "in-space manufacturing" mean, and which kinds of activity does this study cover?
The short answer. the phrase covers three different businesses that are often confused. The first is making things in orbit for use on Earth: drug crystals, tissues, fibre, crystals for chips. The second is making things in orbit for use in space: printed parts, structures, propellant. The third is using orbit as a laboratory, where the product is knowledge that is then applied on Earth. This study focuses on the first and third, which decide whether microgravity can support commercial stations and capsules after 2030. It treats the second, which is a construction and logistics business, briefly. The distinction matters because the economics are completely different: a product for Earth must survive the cost of coming home.
Three businesses under one name
| Business | Product | Customer | Key cost | Example |
|---|---|---|---|---|
| Made in orbit, used on Earth | Physical goods | Pharma, medtech, photonics, chips | Launch plus return per kilogram | Varda capsules, ZBLAN fibre, retina films |
| Made in orbit, used in orbit | Parts, structures, propellant | Station and satellite operators, agencies | Raw material launch; avoided launch of finished parts | 3D printing on the ISS, lunar resource use (Study S8) |
| Orbit as a laboratory | Data, insight, process knowledge | Pharma R&D, universities, agencies | Platform access, crew time | Merck pembrolizumab, protein structures, organoids |
Exhibit 2.1
The laboratory business is easier; the product business is where stations need revenue
Made in orbit for Earth versus orbit as a laboratory
| Made in orbit, used on Earth | Orbit as a laboratory | |
|---|---|---|
| What returns | Product in bulk | Samples and data |
| Budget that pays | Manufacturing and supply | R&D |
| Repeat demand | Every batch | Until the insight is learned |
| Regulation | Full manufacturing rules for medicines | Research rules |
| Example | ZBLAN fibre, retina films | Merck pembrolizumab |
Why the first business is hardest
A product made in orbit for Earth pays twice for transport: once to send up the equipment and raw materials, once to bring the product back. It also pays for the time and risk of the trip, and in medicine it must meet manufacturing rules written for factories on the ground. The value per kilogram of product must be very high, and the product must be impossible, or much harder, to make on Earth. Otherwise a terrestrial competitor will copy the result without the launch bill.
Why the laboratory business is easier, and smaller
Using orbit as a laboratory needs no return of product in bulk: samples come back, and the knowledge travels for free. The customer is an R&D budget, which is smaller but more tolerant of cost. The risk is that once the insight is gained, the customer no longer needs to fly. Merck's experience with pembrolizumab, in which space experiments informed a formulation now made on the ground (Chapter 14), shows both the value and the limit of this model.
What this study counts
| Included | Excluded or brief |
|---|---|
| Pharmaceutical crystallisation and formulation | Satellite servicing and refuelling (Study S12, planned) |
| Biologics, organoids, stem cells, bioprinting | Lunar resource use (Study S8) |
| Implant and biomaterial films | Space-based solar power manufacturing (Study S11, planned) |
| Optical fibre, semiconductor crystals, alloys | Large in-space assembly of structures |
| Platforms: ISS, commercial stations, free-flying capsules | Crewed tourism |
| Re-entry and recovery services | |
| Regulation of space-made products |
The terms used in this study
| Term | Meaning in this study |
|---|---|
| Microgravity | The condition in orbit where objects are in free fall; effective gravity about a millionth of Earth's |
| Free-flyer | An uncrewed spacecraft that processes a payload in orbit without a station |
| Capsule | The part of a free-flyer that re-enters and lands with the product |
| Platform | A station, a free-flyer or a module where processing happens |
| Product | What a customer receives: material, sample or data |
| Replication risk | The chance that a microgravity result can be achieved on Earth by other means |
A reality check from history
Companies have promised microgravity factories since the 1980s, when McDonnell Douglas flew a drug purification experiment on the Space Shuttle and planned a commercial facility that was never built (Chapter 6). The difference in 2026 is that launch is cheap enough (rideshare at about $7,000 per kilogram, Study S5) and re-entry capsules are small and reusable enough that a mission can cost millions rather than hundreds of millions of dollars. Whether that is cheap enough depends on the product, which is the subject of Part II.
What would change this view
A medicine approved with a manufacturing step performed in orbit would move the first business from aspiration to fact. A collapse in capsule costs, for example through reuse at scale, would widen the range of products that can bear the trip. Conversely, ground-based techniques that mimic microgravity, such as magnetic levitation, acoustic levitation and new crystallisation methods, could shrink the set of products that need orbit.